Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Verve-102

A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730)

Trial NCT06164730 (Recruiting) Estimated primary completion: August 2026 Estimated study completion: August 2026 Aim To evaluate the safety and pharmacodynamic profile of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (CAD). Study design Phase 1b, open label, single ascending dose escalation study…

Posted on 31 July 2024 | Posted in Trials, Verve-102

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters